About 72% NOD.Scid mice that were received CD4+ T cells from GAD-BPI-treated mice did not have hyperglycemia (i.e., blood glucose ≥ 250 mg/dl) after 7 weeks while only 17% of NOD.Scid mice did not have hyperglycemia when treated with CD4+ T cells from PBS-treated mice. This evidence concerns the gene GAD1 and Hyperglycemia.